Bolder Biotechnology, Inc.-Product Pipeline Review-2012 New Report
News | 07 February 2013
This report is built using data and information sourced from databases, Bolder Biotechnology, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Bolder Biotechnology, Inc. and industry-specific third ...
Click on the link to read the full article at SBWire (press release)
(This link will open in a new window)
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
